{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.1","upperLimit":"100.0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"title":"Anti-HPV 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.1","upperLimit":"100.0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"title":"Anti-HPV 11"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.0","upperLimit":"100.0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"}],"units":"Participants"}],"title":"Anti-HPV 16"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.1","upperLimit":"100.0","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"title":"Anti-HPV 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.1","upperLimit":"100.0","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"}],"units":"Participants"}],"title":"Anti-HPV 31"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.1","upperLimit":"100.0","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"}],"units":"Participants"}],"title":"Anti-HPV 33"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.1","upperLimit":"100.0","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"193"}],"units":"Participants"}],"title":"Anti-HPV 45"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.1","upperLimit":"100.0","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"192"}],"units":"Participants"}],"title":"Anti-HPV 52"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.1","upperLimit":"100.0","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"title":"Anti-HPV 58"}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"}],"units":"Participants"}],"description":"Seroconversion was defined as a participant who was anti-HPV seronegative at Day 1 and became seropositive at 4 weeks postdose 3 (Month 7). Anti-HPV antibodies were measured using a Competitive Luminex Immunoassay.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6","id":"OG000","title":"9vHPV Vaccine"}],"paramType":"NUMBER","populationDescription":"All allocated participants who were seronegative to the appropriate HPV type at Day 1, received all 3 vaccinations with the correct dose within acceptable day ranges, provided a serum sample within 21 to 49 days postdose 3, and had no protocol deviations that could interfere with the evaluation of participant's immune response to 9vHPV vaccination.","reportingStatus":"POSTED","timeFrame":"4 weeks postdose 3 (Month 7)","title":"Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}